Navigation Links
What is the Optimal Method of Ischemia Evaluation in WomeN: Preliminary Data from the WOMEN Study
Date:9/13/2008

BOSTON, Sept. 13 /PRNewswire-USNewswire/ -- Cardiovascular disease kills more women each year than all cancers combined. Although this statistic is gaining more recognition among physicians and patients, the unique risk factors and symptoms of female patients make diagnosis and prognosis of women with heart disease particularly challenging.

Data from the WOMEN Study: What is the Optimal Method of Ischemia Evaluation in WomeN presented today at the American Society of Nuclear Cardiology Annual Scientific Session seeks to compare exercise stress testing alone or with myocardial perfusion imaging to determine the best method for detecting heart disease in symptomatic women. The study goal is to determine the best method based upon a 2 year follow-up. Researchers will present baseline data from the study, including demographics, pre-test likelihood of coronary artery disease, and initial test results.

"The strength of this study is the large enrollment and careful follow-up to optimize diagnostic strategies in symptomatic women," said Dr. Gary Heller, who will be presenting data at today's meeting on behalf of the four investigators who initiated the study -- Drs. Gary Heller, Robert Hendel, Jennifer Mieres, and Leslee Shaw. "The goal of the study is to improve outcomes in women with coronary artery disease by earlier and better detection."

During a two-year recruitment period, 826 patients were enrolled from 46 sites. Entry criteria were based on American College of Cardiology guidelines and the ability to exercise as determined by the Duke Activity Status (DASI) questionnaire. Women were randomized to either electrocardiogram exercise tolerance testing (ETT) alone or ETT with Tc-99m tetrofosmin SPECT myocardial perfusion imaging. Ongoing results are monitored by a Data Safety and Monitoring Board with all events adjudicated. Major adverse cardiac events will be evaluated at one and two years.

Dr. Gary Heller will present this study,
'/>"/>

SOURCE American Society of Nuclear Cardiology
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Genetics Determine Optimal Drug Dose of Common Anticoagulant
2. Endoscopy Identified as Safe and Effective Method in Treating Common Complication of Gastric Bypass Surgery
3. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
4. Harris Methodist Fort Worth Hospital Using Bubbles to Help Babies Breathe
5. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
6. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
7. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
8. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
9. Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology
10. febit and TGen Collaborate to Study New DNA Capture Method
11. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... , May 26, 2015  AbbVie (NYSE: ... Phase 3 GIFT-I study of its investigational, all-oral, ... treatment with ombitasvir/paritaprevir/ritonavir at the Annual Meeting of ... Japan . 1 GIFT-I evaluated ... infected Japanese patients, with and without cirrhosis, who ...
(Date:5/26/2015)... -- Thoratec Corporation (NASDAQ: THOR ), a world ... and restore failing hearts, said today it will participate ... Conference on Tuesday, June 9. D. ... provide an update on the company, beginning at 2:00 ... The presentation will be available through the ...
(Date:5/26/2015)... , May 26, 2015  Amgen (NASDAQ: AMGN ... the Phase 3 OPTiM study in the Journal ... The data published in JCO , which were ... Society of Clinical Oncology (ASCO) in 2013 and 2014, ... patients with unresected stage IIIB, IIIC or IV metastatic ...
Breaking Medicine Technology:AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 2AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 3AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 4AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 5AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 6Thoratec Presentation At Goldman Sachs Healthcare Conference To Be Webcast 2Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 2Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 3Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 4Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 5Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 6Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 7Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 8
(Date:5/26/2015)... New York (PRWEB) May 26, 2015 ... ( http://www.xareltolawsuit2015.com/ ) filed on behalf of individuals who ... for the litigation’s June 11th Science Day. According to ... District of Louisiana, on May 21st, topics to be ... the drug, the use of blood test based testing ...
(Date:5/26/2015)... 26, 2015 Now offering innovative, safe, ... center of Dr. Hedi Belajouza in Tunisia ... , Perfection to the last detail — meticulous hair ... location of the harvested follicle — are all results ... predominantly visible in the artistry and talent of Tunisian ...
(Date:5/26/2015)... San Francisco, CA (PRWEB) May 26, 2015 ... interested students to join them for the Open House/Free Application ... 11 a.m. and go until 4 p.m. and will be ... in San Francisco, CA. , After checking in, attendees will ... will then be a tour of the campus at 11:45 ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Marching ... the summer season, and thanks to the efforts ... solutions, more of their musicians are protecting their ... With over 400 participating groups, Etymotic’s Adopt-a-Band program ... by Etymotic are now for sale in drum ...
(Date:5/26/2015)... 3,000 senior industry executives are expected at the ... of the connected car. A very special attraction for ... read a driver’s brain waves. Visitors to its booth ... mind alone just by gripping the steering wheel! , ... working on cognitive load, altering music based on the ...
Breaking Medicine News(10 mins):Health News:Federal Xarelto Lawsuits Move Forward, as Court Establishes Procedures for Upcoming Science Day 2Health News:Federal Xarelto Lawsuits Move Forward, as Court Establishes Procedures for Upcoming Science Day 3Health News:Federal Xarelto Lawsuits Move Forward, as Court Establishes Procedures for Upcoming Science Day 4Health News:Hair Transplant Center in Tunisia Now Offering Innovative Restoration Technology 2Health News:Hair Transplant Center in Tunisia Now Offering Innovative Restoration Technology 3Health News:Hair Transplant Center in Tunisia Now Offering Innovative Restoration Technology 4Health News:ACTCM to Host Summer Open House 2Health News:Marching Musicians Getting In Step With Hearing Protection 2Health News:The World’s Biggest Connected Car Exhibition is Back in Detroit 2Health News:The World’s Biggest Connected Car Exhibition is Back in Detroit 3
... , , BIRMINGHAM, Ala., Sept. 21 ... that it has been awarded a $77.2 million contract modification by ... Phase 3 development of its influenza neuraminidase inhibitor, intravenous (i.v.) peramivir, ... "We are very excited to continue working with the ...
... , BOSTON, Sept. 21 SmarterTravel(R), a comprehensive ... for staying safe while traveling during this highly anticipated flu season. , ... Check your health insurance: Before you depart, ... case you develop the swine flu, or any illness, while traveling. , ...
... ... New England Office and Offers Assistance to 3 Local Companies , ... (Vocus) -- Omnion Consulting ... even subsisting, is offering 1 day (8 hours) of free strategic consulting to 3 ...
... collection of fluid around the heart, typically occurs in ... an invasive surgical drainage technique. However researchers have discovered ... is just as effective requiring no ... cost savings over the surgical drainage technique, according to ...
... , Second Annual Event Promotes Adaptive ... Sept. 20 Secretary of Veterans Affairs Eric K. Shinseki offered encouragement ... the 2nd National Veterans Summer Sports Clinic in San Diego. Calling ... kicked-off the clinic by telling his personal story of dealing with a ...
... toxic for some: study , SUNDAY, Sept. 20 ... women with advanced ovarian cancer, Japanese researchers say. ... weeks is considered standard first-line chemotherapy for advanced ... paclitaxel is seen as a way to increase ...
Cached Medicine News:Health News:BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza 2Health News:BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza 3Health News:BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza 4Health News:BioCryst Awarded Additional $77.2 Million by the U.S. Department of Health & Human Services To Develop Peramivir for Influenza 5Health News:Travel Precautions Critical During Swine Flu Season 2Health News:Travel Precautions Critical During Swine Flu Season 3Health News:New England Business Offers Free Service to Companies in Need 2Health News:Secretary Shinseki Kicks-Off National Sports Clinic 2Health News:New Chemo Regimen May Benefit Ovarian Cancer Patients 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: